2019
DOI: 10.1111/bju.14811
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: ObjectivesTo develop a risk classifier using urine‐derived extracellular vesicle (EV)‐RNA capable of providing diagnostic information on disease status prior to biopsy, and prognostic information for men on active surveillance (AS).Patients and MethodsPost‐digital rectal examination urine‐derived EV‐RNA expression profiles (n = 535, multiple centres) were interrogated with a curated NanoString panel. A LASSO‐based continuation ratio model was built to generate four prostate urine risk (PUR) signatures for pred… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
35
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 30 publications
(36 citation statements)
references
References 39 publications
(84 reference statements)
1
35
0
Order By: Relevance
“…ExoMeth was able to correctly predict the presence of significant prostate cancer on biopsy with an AUC of 0.89, representing a significant uplift when compared to other published tests (AUCs for Gs ≥ 7: PUR = 0.77, 23 ProCUrE = 0.73, 14 ExoDX Prostate IntelliScore = 0.77, 13 SelectMDX = 0.78, 12 epiCaPture AUC = 0.73 [Gs ≥4 + 3] 22 ). Furthermore, ExoMeth resulted in accurate predictions even when serum PSA levels alone were inaccurate; where patients with a raised PSA but negative biopsy result possessed similar ExoMeth scores as clinically benign men, while still able to discriminate between Gleason grades (Figure 4).…”
Section: Discussionmentioning
confidence: 98%
See 4 more Smart Citations
“…ExoMeth was able to correctly predict the presence of significant prostate cancer on biopsy with an AUC of 0.89, representing a significant uplift when compared to other published tests (AUCs for Gs ≥ 7: PUR = 0.77, 23 ProCUrE = 0.73, 14 ExoDX Prostate IntelliScore = 0.77, 13 SelectMDX = 0.78, 12 epiCaPture AUC = 0.73 [Gs ≥4 + 3] 22 ). Furthermore, ExoMeth resulted in accurate predictions even when serum PSA levels alone were inaccurate; where patients with a raised PSA but negative biopsy result possessed similar ExoMeth scores as clinically benign men, while still able to discriminate between Gleason grades (Figure 4).…”
Section: Discussionmentioning
confidence: 98%
“…Up to 75% of men with a raised PSA (≥4 ng/mL) are negative for prostate cancer on biopsy 4,5,37 . This has resulted in concentrated research efforts to address this problem noninvasively and the development of several biomarker panels capable of detecting Gleason ≥3 + 4 disease with superior accuracy to current clinically implemented methods 11‐13,23 . However, in each of these examples, only a single quantification method or biological process is assayed and with the molecular heterogeneity of prostate cancer considered, 38 a more holistic approach is necessary.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations